Eikon Therapeutics, Inc. (EIKN)
Nasdaq · Healthcare · Biotechnology
$7.54+2.86%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $408M
- 52-week range
- $7.02 – $17.40
- 52-week change
- −51.13%
- EPS (trailing)
- −$8.77
- Next earnings
- Nov 12, 2026
About Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
Headquarters: Millbrae, United States · 384 employees · eikontx.com